Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

A possible benchmark for Barrett’s esophagus surveillance

Key clinical point: Missed dysplasia or esophageal adenocarcinoma could lead to greater disease burden.

Major finding: The neoplasia detection rate was 4.9%.

Study details: A retrospective analysis of data from 11 counties in Minnesota (1,066 patients).

Disclosures: The study was funded by the National Cancer Institute and the National Institute of Aging. Dr. Mosko has no relevant financial disclosures.


Dhaliwal L et al. Clin Gastro Hepatol. 2020 Jul 21. doi: 10.1016/j.cgh.2020.07.034.